Workshop on conformity assessment procedures and certification of medical devices INT MARKT 43755 Kyiv, 28-29 November 2011 In Vitro Diagnostic Directive.

Slides:



Advertisements
Similar presentations
European Commission Jacques McMillan Enterprise Directorate-General Legal aspects linked to internal market EUROPEAN CONFERENCE ON MARKET SURVEILLANCE.
Advertisements

The regulation of medical devices in Australia. Overview Comparing medicines and medical devices What is a medical device? Statistics on patients requiring.
SALDA In Vitro Diagnostics in South Africa Welcome 5 November 2014 Portfolio Committee Bill
Case Study: The Binding Site. Working with the Recast/Revision of the IVD Directive - the Impact on a Medium- sized Diagnostics Company Dr Kirk Buller.
IVD and Point of care testing
Options for Regulation and the Impact of Regulation on the Marketplace 29 November 2005 Alan Kent
DATA PROTECTION and Research University Research Ethics Committee – David Cauchi Office of the Data Protection Commissioner.
Supervision of the quality of water intended for human consumption by State Sanitary Inspection bodies Małgorzata Kedzierska Environmental Hygiene Dept.
CE Marking for Medical Devices “Basic Steps to Compliance” Ján Petrík, PhD. EVPÚ, a.s. Nová Dubnica Medical Devices Branch Office Bratislava 4/27/06 EVPÚ,
EU Regulatory Environment—2008
CE2012 – Thursday 20 September The In Vitro Diagnostics View Doris-Ann Williams Chief Executive, BIVDA CC Celebrating 20 years representing the IVD industry.
張明正 工程師 工研院量測中心/醫療器材驗證室
CE marking Catriona Blake Team Manager, Imaging, acute and community care.
Good Manufacturing Practices for Blood Establishments
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
The New EMC Directive 2004/108/EC and the DTI transposition Brian Jones and Peter Howick.
ENTERPRISE AND INDUSTRY DIRECTORATE GENERAL European Commission Anna Solé Mena Policy Officer - European Commission DG Enterprise and Industry.
STATE OF THE ART AND PERSPECTIVES IN MEDICAL DEVICE LEGISLATION 3rd National Conference on Medical devices Roma, 13th April 2010 Sabine Lecrenier Head.
Q&A REGULATORY AFFAIRS IN LATIN AMERICA. DEFINITION OF MEDICAL DEVICE Product, equipment, device, material, article or system of Medical, Odontological.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Regulatory Overview.
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.
Changes to the Therapeutic Goods Act and its implications Prepared by: Anna Frazer Prosthetist Hunter Prosthetics & Orthotics Service 10 th November 2006.
1 CONSENSUS STANDARDS OIVD WORKSHOP April 22-23, 2003 Rockville MD Ginette Y. Michaud, M.D. OIVD.
SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B March 2012.
© 2015 BELGORAIL 27/04/2015 – BEWAG « Staff (human) in the ECM regulation 445/20111/EU» Staff (human) in the ECM regulation.
The concept for a network of national Reference Laboratories for high risk IVDs – Results of the working group meeting 1.
Assemblies Intentions and enforcement. Intentions Free movement  CE marking for vessels, accessories and assemblies Well-defined responsibilities  Manufacturer,
SALDA Presentation to the Honourable Portfolio Committee on Health
EU Seveso II Directive Operators obligations & Competent Authorities duties 2.3 Activity workshop Angeliki Tsatsou Dritsa Chemist, TA Key Expert 2 Zagreb.
Chapter 18 Regulations Tracking. Regulations US: FDA, almost all devices, almost all drugs European Community: devices so far, CE mark is the goal. –Active.
WHO - PSM Materials Pharmaceutical Quality, Good manufacturing Practice & Bioequivalence Kiev, Ukraine October 2005 Maija Hietava M.Sci.Pharm Quality.
Prof R T KennedyEMC & COMPLIANCE ENGINEERING 1 EET 422 EMC & COMPLIANCE ENGINEERING.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
Development of Agreement Concerning the Adoption of Uniform Conditions for Periodical Technical Inspections of Wheeled Vehicles and the Reciprocal Recognition.
Authorization Part III. Content of a license Structure of a license General elements General and specific conditions Annexes Documents attached (e.g.
CE mark issues -- PEI view
06/02/20161 Benny Hoff TÜV NORD Sweden AB AFS 2005:2 Installations.
Agreement concerning the adoption of uniform conditions for periodical technical inspections of wheeled vehicles and the reciprocal recognition of such.
Visit us at E mail: Tele:
Laboratory equipment Dr. W. Huisman Cairo, November 21th 2012.
CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser Ministry of Health, ROMANIA.
European Diagnostic Manufacturers Association EQA contribution and industry expectations Dr. Claude GIROUD – Chairman Standardization, Quality & Risk Management.
THE OFFICE FOR REGISTRATION OF MEDICINAL PRODUCTS, MEDICAL DEVICES AND BIOCIDAL PRODUCTS Responsibility in the handling of medical devices.
CONSIDERATIONS FOR SURGICAL MEDICAL DEVICE TRIALS LCTU Liverpool Clinical Trials Unit Considerations for Medical Device Trials.
©drs.nu, April Introduction to EU Regulation for Wearables.
Czech Office for Standards, Metrology and Testing Prague/Czech Republic.
Workshop on conformity assessment procedures and certification of medical devices INT MARKT Kyiv, November 2011 Conformity assessment of medical.
REGULATION (EC) Nº 1223/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 30 November 2009 on cosmetic products 1 Shall apply from 11.
PD233: Design of Biomedical Devices and Systems (Lecture 2) Dr. Manish Arora CPDM, IISc Course Website:
Health and Consumers Health and Consumers Introduction to the new Medical Device Regulations and their impact on medical software DG for Internal Market,
Health and Consumers Health and Consumers Introduction to the new regulatory framework for medical devices and in vitro diagnostic medical devices DG for.
Director, Regulatory Affairs
Department of Engineering
Flowchart on overview of requirements
Strategy for conformity of non-standard cryogenic equipment
The New Legislative Framework Miniseminar New Legal Framework Reykjavík, 10 December 2008 Doris Gradenegger Unit C1: Regulatory Approach for the Free.
EU legislation on Personal Protective Equipment (PPE)
TÜVRheinland® The Trusted Name In Product Safety Testing and Management System Certifications Worldwide. EU - Regulatory Update Amendment to the Medical.
Proposal for a Regulation on medical devices and Proposal for a Regulation on in vitro diagnostic medical devices Key Provisions and GIRP Assessment.
Assemblies Intentions and enforcement
Drug-device combinations regulated as medicines - Revised regulatory
Mattias Skafar Head of Quality Division
MEDICAL DEVICES CONTROL SYSTEM IN INDONESIA
Electronic medical equipment.
2.1. Monitoring of products placed on the market To verify the products comply with applicable directives EC declaration of conformity and technical.
mHealth subject to European regulation Dutch Stefan Visscher, PhD
Presentation transcript:

Workshop on conformity assessment procedures and certification of medical devices INT MARKT Kyiv, November 2011 In Vitro Diagnostic Directive 98/79 EC Jos Kraus Former Senior inspector Medical Technology Academic Medical Hospital; Amsterdam The Netherlands

Articles Definitions; article 1 Conformity assessment procedures; article 9 Annexes Essential requirements; Annex I “Classification”; Annex II Declaration of conformity; Annex III Quality system route; Annex IV Performance evaluation (~“clinical study”); Annex VIII Structure 2

‘In vitro diagnostic medical device’ means any medical device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment, or system, whether used alone or in combination, intended by the manufacturer to be Definitions 3

......to be used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information: Concerning a physiological or pathological state, or Concerning a congenital abnormality, or To determine the safety and compatibility with potential recipients, or To monitor therapeutic measures Definitions 2 4

Products for general laboratory use, IVD’s for forensic/military purpose, Products for research only Material used to collect or provide access to the specimen, BUT specimen collectors for primary containment are IVD’s (e.g. vacuum tubes) IVD (home brewed) is not subject to this Directive What is not an IVD 5

Definition of a medical device (old version) Classification rules are missing Annexes are not in the same ordering Annex II is “classification” versus Annex IX Annex III is similar to Annex II (quality system) Differences with 93/42 6

Essential requirements; Same principle of intrinsic safety, Risk based approach, Avoiding residual risk by design, Design is state of the art, Traceability to reference material of a higher order; a problem. Annex I: essential requirements 7

Chemical and physical properties, Infection and microbial contamination, Manufacturing and environmental properties, Devices with a measuring function, Protection against radiation, Devices connected to or equipped with an energy source, Requirements for devices for self-testing, Information supplied by the manufacturer, Annex I 8

List A Reagents and reagent products, including related calibrators and control materials for the determination the following blood groups: ABO system, rhesus (C,c,D,E,e) anti-kell, Reagents for the detection, conformation and qualification in human specimens of markers of HIV infection (HIV 1 and 2), HTLV1 and II, and hepatitis B, C and D Annex II, High Risk 9

Determining of blood groups... Anti-erythrocytic antibodies, Congenital infections: rubella, toxoplasmosis, Phenylketonuria, Cytomegalovirus, Chlamydia, HLA tissue groups: DR, A, B, PSA, Trisomy 21, Self-diagnosis device …. blood sugar Annex II; Medium Risk; List B 10

Annex III point 6 (not applicable for List A and B) Test reports (including results of studies with lay persons; were appropriate) Self testing 11

Product identification data Evaluation plan List of laboratories Starting date and duration Location and number of persons involved (in case of device for self-testing) Statement about safety and performance All documents are available for CA’s and must be kept for 5 years after end of tests Annex VIII; Performance Evaluation 12

Notified by the Competent Authority Only for Annex II List A Batch release (!) List B And Self-diagnosis tests Most of the NBs work together with National institutes; like Paul Ehrlich, Pasteur and Sanguin. Notified Body 13

Annex II is limited in time CJD, SARS, N1H1 are all low risks IVD by definition State of the art is not defined Different HIV tests in the market with different sensitivity Home Brew IVD’s and ‘for research only’ The ‘back door’ of the system “Split testing” Limitations 14

Medical devices General Product Safety Directive (GPSD) Medicinal Products Personalised medicine Biocides Borderlines 15

IVD directive Different group of products Needs revision (is already on going) Definitions no longer in line with 93/42 New risks; not addressed properly Need of a timeless classification structure Same philosophy as the other medical devices Manufacturer is responsible Third party involvement Conclusion 16

I thank you for your attention